Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients
Han-Yang LIANG1
Dong LIU1
Hao WANG1
Zheng-Qing BA1
Ying XIAO1
Yi-Lu LIU1
Yong WANG2
Jian-Song YUAN2
1.State Key Laboratory of Cardiovascular Disease,Fuwai Hospital,National Center for Cardiovascular Disease,Chi-nese Academy of Medical Science and Peking Union Medical College,Beijing,China2.State Key Laboratory of Cardiovascular Disease,Fuwai Hospital,National Center for Cardiovascular Disease,Chi-nese Academy of Medical Science and Peking Union Medical College,Beijing,China;Key Laboratory of Pulmonary Vascular Medicine,Fuwai Hospital,National Center for Cardiovascular Disease,Chinese Academy of Medical Science and Peking Union Medical College,Beijing,China
摘要：BACKGROUND Both lung cancer and cardiometabolic diseases are leading causes of death in China,and they share some com-mon risk factors.However,the prevalence and long-term effect of pre-existing cardiometabolic comorbidities(CMCs)on the surv-ival of middle-aged and elderly lung cancer patients are still not clear.
METHODS We consecutively recruited 3477 non-small cell lung cancer(NSCLC)patients between January 2011 and December 2018 from four cancer specialty hospitals in China.Univariable and multivariable adjusted Cox proportional hazard models were conducted to evaluate the risk factors associated with mortality.Hazard ratio(HR)for mortality and corresponding 95％CI were calculated.
RESULTS The prevalence of CMCs was 30.0％in middle-aged NSCLC patients and 45.5％in elderly NSCLC patients.Log-rank analysis presented statistically significant differences in median survival time between patients with CMCs and without CMCs in both the middle-aged group(21.0 months vs.32.0 months,P＜0.01)and the elderly group(13.0 months vs.17.0 months,P=0.01).Heart failure(HR=1.754,95％CI:1.436-2.144,P＜0.001)and venous thrombus embolism(HR=2.196,95％CI:1.691-2.853,P＜0.001)were independent risk factors for the survival of middle-aged NSCLC patients,while heart failure(HR=1.709,95％CI:1.371-2.130,P＜0.001)continued to decrease overall survival in the elderly group.Hyperlipidemia may be a protective factor for surv-ival in middle-aged group(HR=0.741,95％CI:0.566-0.971,P=0.030).
CONCLUSIONS Our findings demonstrate for the first time the prevalence and prognostic value of pre-existing CMCs in Chi-nese middle-aged and elderly NSCLC patients.
机标关键词：cancercellcardiometaboliccomorbiditieselderlylungmiddle-agednon-small
论文发表日期：2023-10-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：11( 737-747 )